Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes
Question
Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes
Direct answer
Positive Phase III obesity efficacy data de-risks regulatory approval and unlocks milestone payments for partner Zealand Pharma. — bullish pressure on ZLDPY via commercialization royalty stream valuation and milestone payments on Phase III clinical success.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes”, revision 1, evidence through 2026-10-01. https://marketontology.com/catalysts/2026-10-01/survodutide-achieves-13-1-weight-loss-in-phase-iii-trial-for-obesity-and-diabete-6da263
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ZLDPY | ▲Bull | 1–4 weeks | commercialization royalty stream valuation and milestone payments on Phase III clinical success | 68 |
Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes
Positive Phase III obesity efficacy data de-risks regulatory approval and unlocks milestone payments for partner Zealand Pharma. — bullish pressure on ZLDPY via commercialization royalty stream valuation and milestone payments on Phase III clinical success.
Zealand Pharma co-developed survodutide with Boehringer Ingelheim.
- SourceZealand Pharma co-developed survodutide with Boehringer Ingelheim.
- TransmissionPositive Phase III obesity efficacy data de-risks regulatory approval and unlocks milestone payments for partner Zealand Pharma.
- SummaryBoehringer Ingelheim and Zealand Pharma reported Phase III SYNCHRONIZE-2 trial data for survodutide. Patients achieved up to 13.1% weight loss at 76 weeks compared to 3.1% for placebo. The dual glucagon/GLP-1 agonist also produced significant glycemic control improvements.
- ZLDPYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- ZLDPY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ZLDPY price vs. pre-event level
- ZLDPY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss · press_release · 2026-10-01
Related catalysts
- 2026-10-01Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D ObesityZLDPY
- 2026-10-01Survodutide Delivers Up to 13.1% Weight Loss in Phase III TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes CohortZLDPY
- 2026-10-01Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III TrialZLDPY
- 2026-10-01Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D TrialZLDPY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.